Get the Stockscreener App
1.56
4.88%
-0.08
After Hours:
1.65
0.09
+5.77%
Tuhura Biosciences Inc stock is traded at $1.56, with a volume of 363.01K.
It is down -4.88% in the last 24 hours and up +254.55% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$1.64
Open:
$1.61
24h Volume:
363.01K
Relative Volume:
0.25
Market Cap:
$88.11M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.70%
1M Performance:
+254.55%
6M Performance:
-38.82%
1Y Performance:
-26.07%
1-Day Range:
$1.47
$1.65
1-Week Range:
$1.37
$1.8298
52-Week Range:
$0.41
$4.44
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.56 | 92.62M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
HURA Technical Analysis & ETF Price Forecast - Intellectia AI
TuHURA Biosciences stock gains after Nasdaq compliance - Investing.com India
Update Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
TuHURA Biosciences regains Nasdaq listing compliance - Investing.com
Cancer immunotherapy firm TuHURA keeps share price over $1 to satisfy Nasdaq - Stock Titan
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - Nasdaq
HURA.O Technical Analysis & Stock Price Forecast - Intellectia AI
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - MarketBeat
TuHura files IND for leukemia drug combination study By Investing.com - Investing.com India
TuHura files IND for leukemia drug combination study - Investing.com Australia
Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers - marketscreener.com
New TuHURA antibody aims to boost leukemia drug response - Stock Titan
Is TuHURA Biosciences Inc. a strong growth stockJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
HURA PE Ratio & Valuation, Is HURA Overvalued - Intellectia AI
HURA Should I Buy - Intellectia AI
Should I trade or invest in TuHURA Biosciences Inc.2025 Earnings Impact & Free Community Consensus Stock Picks - mfd.ru
Will TuHURA Biosciences Inc. (PL3) stock sustain bullish trend into 2025 - mfd.ru
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Malaysian Reserve
Will TuHURA Biosciences Inc. stock maintain dividend yieldWeekly Trend Recap & Risk Managed Investment Signals - mfd.ru
HURA Stock Strongly Rises on Early Morning Surge - timothysykes.com
Is TuHURA Biosciences Inc. stock cheap at current valuationWeekly Trend Summary & Breakout Confirmation Alerts - mfd.ru
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Market Review: How volatile is Draganfly Inc stockTrade Risk Assessment & Smart Swing Trading Alerts - baoquankhu1.vn
FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results - streetwisereports.com
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug By Investing.com - Investing.com South Africa
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - MEXC
TuHURA Receives FDA Orphan Drug Designation - Intellectia AI
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug - Investing.com
Quarterly Earnings: What dividend growth rate does TuHURA Biosciences Inc offer2025 Volume Leaders & Trade Opportunity Analysis - baoquankhu1.vn
TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice - TipRanks
TuHURA Biosciences Received Notice of Noncompliance - TradingView
Will TuHURA Biosciences Inc. outperform its industry peers2025 Volume Leaders & Safe Capital Investment Plans - mfd.ru
Risk Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Breakout Watch: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
TuHURA Biosciences (NASDAQ:HURA) Shares Up 0.5% – Here’s Why - Defense World
MACD Signal: Will TuHURA Biosciences Inc outperform its industry peers2025 Historical Comparison & Verified High Yield Trade Plans - baoquankhu1.vn
Will TuHURA Biosciences Inc. stock gain from lower inflation2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Will TuHURA Biosciences Inc. stock benefit from green energy trendsQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is TuHURA Biosciences Inc. stock supported by innovation pipelinePrice Action & Verified Momentum Stock Alerts - ulpravda.ru
HURA: Analyst Reiterates Buy Rating, Lowers Price Target | HURA Stock News - GuruFocus
Risk Hedge: Will TuHURA Biosciences Inc. (PL3) stock attract long term capital inflows - Улправда
Can TuHURA Biosciences Inc. (PL3) stock expand revenue streams2025 Historical Comparison & Weekly High Return Stock Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock is popular among millennialsTake Profit & AI Driven Stock Price Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock could see breakout soonMid Cap Growth Trends & Rapid Capital Gain - ulpravda.ru
TuHURA Biosciences Inc Stock Analysis and ForecastRetail Trading Trends & Enter Your Email to Get Stock Alerts - earlytimes.in
Tuhura Biosciences amends loan agreement, secures full $3M - MSN
Is TuHURA Biosciences Inc PL3 a good long term investmentStop Loss Placement Tips & Big Profit Small Investment - earlytimes.in
What the Latest News Means for ABS Marine Services Limited Stock InvestorsTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
TUHURA Biosciences announces $15.6M registered direct offering - MSN
What analysts say about TuHURA Biosciences Inc PL3 stockEvening Star Patterns & Don’t Miss These Undervalued Stocks - earlytimes.in
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):